

Global Myasthenia Gravis Treatment Market: Forecast and Trends

Market Research Report | 2023-11-23 | 120 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.

Report Includes:

- 54 data tables and 47 additional tables
- An overview and analysis of the global market for myasthenia gravis (MG) treatments
- Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
- In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
- Analysis of the market growth opportunities through Porter's Five Forces and PESTLE analyses, taking into consideration the prevailing micro- and macro environmental factors
- An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
- Discussion of the factors driving the market, industry trends and new developments
- Analysis of relevant patents
- Identification of the leaders in the field of MG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva

Executive Summary

Summary:

The market for myasthenia gravis (myasthenia gravis) treatments had an estimated value of \$REDACTED billion in 2022 and is projected to grow to \$REDACTED billion in 2028.

The global market for myasthenia gravis treatments was valued at nearly \$REDACTED billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED%, reaching \$REDACTED billion in 2028. Growth in this market is fueled by a worldwide increase in elderly populations and an increased prevalence of myasthenia gravis.

Technological innovation is an important catalyst driving adaptation and use.

In 2022, the generalized myasthenia gravis segment held the highest market share at about REDACTED%, followed by ocular myasthenia gravis at REDACTED% and transient neonatal myasthenia gravis at REDACTED%

Table of Contents:

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Report Highlights
Chapter 3 Market Overview
Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pricing and Reimbursement for the Treatment of Myasthenia Gravis

North America

Europe

Asia-Pacific

Therapies/Drugs Used to Treat Myasthenia Gravis

Medications

Surgery

Intravenous (IV) Therapy

Medications

Chapter 4 Market Dynamics

Market Drivers

Growing Elderly Population

Increasing Incidence and Prevalence

Advancements in Myasthenia Gravis Diagnostics

Research and Development

Regulatory Environment

Personalized Medicine

Market Opportunities

Unmet Medical Needs

Advancements in Research and Development

Biologics and Immunotherapies

Global Expansion

Increased Awareness

Tailored Treatment Approaches

Healthcare Reimbursement

Patient-Centric Care

Competitive Landscape

Chronic Nature of Myasthenia Gravis

Research Collaboration

Market Restraints

Limited Patient Population

Diagnostic Challenges

Lack of Disease-Modifying Therapies

Reimbursement Issues

Risks of Emerging Therapies

Other Restraints

Chapter 5 Market Breakdown by Region

Market Overview

North America

Europe

Asia-Pacific

Chapter 6 Market Breakdown by Type

Market Overview

Generalized Myasthenia Gravis

Transient Neonatal Myasthenia Gravis

Ocular Myasthenia Gravis

Chapter 7 Market Breakdown by Treatment Modality

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Introduction
Medications
Surgery
Intravenous Therapy
Chapter 8 Market Breakdown by Type of Product
Monoclonal Antibodies
Brands
Cholinesterase Inhibitors
Brand
Intravenous Immunoglobulins
Brands
Immunosuppressants
Brand
Corticosteroids
Brand
Chapter 9 ESG Development
Introduction
Environment
Social
Governance
Case Study
AstraZeneca
Concluding Remarks from BCC Research
Chapter 10 Emerging Technologies and Developments
Introduction
Chapter 11 Competitive Intelligence
Overview
Industry Scenario
Company Shares
Chapter 12 Patent Analysis
Patent Analysis by Manufacturer
Chapter 13 Pipeline Analysis
Clinical Trials
Chapter 14 M&A and Venture Funding Outlook
Introduction
Chapter 15 Company Profiles
ABBVIE
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB
CSL
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 16 Appendix: Acronyms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Myasthenia Gravis Treatment Market: Forecast and Trends

Market Research Report | 2023-11-23 | 120 pages | BCC Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com